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Hepatic veno-occlusive disease (VOD), also known as
sinusoidal obstruction syndrome, is a potentially life-
threatening complication after hematopoietic stem cell
transplantation (HSCT). VOD affects both adult and pediatric
populations alike, with a higher incidence in the allogeneic
setting [1]. Disease onset is typically within the ﬁrst 30 days
after HSCT [1], although later occurrence has been reported
[2]. It is characterized by clinical features such as hepato-
megaly, jaundice, weight gain, and ascites [3,4]. VOD is re-
ported to occur in 8% to 14% of patients after HSCT [3],
although incidence rates may be as high as 60% in higher-risk
patients (such as those with underlying liver disease and
certain speciﬁc drug exposures, including gemtuzumab,
ozogamicin, and sirolimus) and depending on the diagnostic
criteria used [3,4]. Severe VOD (sVOD) is typically associated
with multiorgan failure (MOF) and high mortality rates
(>80%) [3,4]. Even among patients with moderate VOD, the
mortality rate is still estimated at approximately 20% [5].PATHOGENESIS
VOD is thought to be triggered by activation and damage
to the sinusoidal endothelial cells in zone 3 of the hepatic
acinus due to conditioning regimenemediated injury [6].
Activated sinusoidal endothelial cells express cytokines (eg,
tumor necrosis factor-a and interleukin-1b) and adhesion
molecules (eg, intracellular adhesion molecule 1 [ICAM-1]
and vascular cell adhesion protein 1 [VCAM-1]), resulting in
activation of proinﬂammatory pathways that further damage
the endothelium [7]. This leads to the loss of endothelial wall
fenestrae and formation of gaps between sinusoidal endo-
thelial cells [2]. Consequently, red blood cells, leukocytes,
and cellular debris extravasate into the space of Disse,
causing progressive extraluminal compressive narrowing of
the sinusoids [2,7,8] and dissection of the endothelial cell
lining cells, which could further embolize downstream and
occlude the sinusoid [2]. In addition, injury to the sinusoidal
endothelial cells of the sinusoids is also associated with
a procoagulant and hypoﬁbrinolytic state that contributes
further to ﬁbrin deposition, clot formation in situ, and nar-
rowing of the sinusoids [6-8]. Together, these effects reduce
hepatic venous outﬂow, leading to postsinusoidal hyper-
tension, central venular-occlusion, hepatic enlargement with
capsular distension, and, in more severe cases, portal venousFinancial disclosure: See Acknowledgments on page S89.
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DIAGNOSIS AND PROGNOSIS OF VOD
The diagnosis of VOD is often made based on clinical
criteria; the Seattle criteria stipulate that at least two ormore
clinical features, including jaundice, painful hepatomegaly or
ascites, and/or unexplained weight gain, must be evident
within 30 days of transplantation [8,9]. Conversely, the more
rigorous Baltimore criteria specify an elevated bilirubin level
of at least 2.0 mg/dL and two or more of the following
characteristics: hepatomegaly, ascites, or at least 5% weight
gain by day þ21 post-HSCT, with the Baltimore criteria
validated according to both histopathologic features and
outcome [8,10].
VOD presents with a wide spectrum of severity and is
conventionally divided into mild, moderate, and severe
disease [11]. Mild VOD is considered disease that meets
diagnostic criteria, does not require speciﬁc treatment for
ﬂuid excess or medication for hepatic pain, and has a self-
limiting course. Moderate VOD is disease with evidence
of liver injury that requires active treatment for ﬂuid excess
or medication for hepatic pain but that usually resolves
completely. sVOD is deﬁned as disease that is usually
associated with MOF, severe hyperbilirubinemia with rapid
weight gain, and typically leads to death [12]. Although
several biomarkers of endothelial injury, such as plasmin-
ogen activator inhibitor type-1, have been shown to be
elevated in patients with VOD [13,14], no laboratory marker
has been standardized or validated as a diagnostic indica-
tion of VOD. Based on retrospective analyses, the presence
of MOF has emerged as the best clinical marker for VOD
severity to date. The Bearman model, which estimates the
risk of developing sVOD based on bilirubin level,
percentage weight gain, and a designated time frame from
HSCT, has also demonstrated utility for predicting VOD
severity. However, because the Bearman model was
developed in a cohort of patients who developed VOD
within 17 days of HSCT after speciﬁc conditioning regi-
mens, its general applicability to other conditioning regi-
mens and later time frames post-HSCT is limited [3,4,15]. In
this context, sensitive and speciﬁc biomarker assays are
needed that could guide disease prognostication and
management, with some candidate markers under study
but none yet deﬁned.
TREATMENT OPTIONS AND PATIENT MANAGEMENT
Current management of VOD consists primarily of
supportive care, with a focus toward ﬂuid management,
adequate oxygenation and transfusional support tominimizeTransplantation.
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[12,16]. The use of tissue plasminogen activator with or
without heparin has been evaluated in a number of studies
and small case series. However, results have generally been
disappointing; although about one-third of patients show
improvement in their VOD with thrombolytic therapy, life-
threatening hemorrhages are common, and no survival
advantage is apparent [12].
Although no agents to date have been approved for the
treatment of VOD either in the United States or the European
Union, the investigational drug deﬁbrotide (DF) has shown
the most promising results in clinical trials to date. DF is
a polydisperse oligonucleotide with ﬁbrinolytic properties
(but no signiﬁcant systemic anticoagulation) that has also
demonstrated protective effects on micro- and macro-
vascular endothelium. The use of DF for the treatment of VOD
is supported by a number of large clinical trials showing
that DF improves both complete response (CR) and
survival. These include a large multicenter, prospective,
randomized phase II study that established an effective DF
dose of 25 mg/kg/day in divided doses administered intra-
venously every 6 hours [16].
Promising studies using historical controls [17,18] and,
more recently, a multicenter, randomized, prospectively
controlled trial in children [5] demonstrated the efﬁcacy of
DF for prophylaxis of VOD. As such, orphan drug status has
been granted for DF for the treatment and prophylaxis of
VOD by both the European Medicines Agency [19,20] and US
Food and Drug Administration [21].
The use of DF for the treatment of VOD is further sup-
ported by a large number of clinical trials showing that DF
improves both CR and survival. The efﬁcacy of DF for the
treatment of sVOD was ﬁrst demonstrated in a retrospective
dose escalation study of 19 patients with sVOD and MOF
performed in the United States that showed complete
resolution of VOD in 8 patients (42%), 6 of whom survived
for longer than 100 days with no signiﬁcant bleeding
observed [22]. A number of trials have subsequently
conﬁrmed the efﬁcacy of DF in this setting, including
a similar European multicenter compassionate-use study,
which treated 40 patients and demonstrated a 55% CR rate,
with 43% patients alive after 100 days [23]. Importantly,
a recent pivotal phase III, historically controlled trial of DF in
102 patients with sVOD/MOF showed a superior 100-day CR
rate in the DF group compared with historical controls (24%
vs 9%, respectively; adjusted P ¼ .015) and a lower 100-day
mortality rate with DF compared with historical controls
(62% vs 75%, respectively; adjusted P ¼ .051) [24]. Recog-
nizing VOD with MOF as a life-threatening condition with
no other effective treatment options, the US Food and Drug
Administration permitted access to DF in the United States
through an investigational new drug compassionate-use
treatment protocol in December 2007. An interim analysis
of 269 patients enrolled between December 2007 and
March 2011 at 67 US centers revealed that 32% of patients
achieved a CR at day-100 post-HSCT, with an overall day-
100 survival of 50% [25]. From this protocol, 134 patients
would have met entry criteria for the pivotal phase III trial,
and comparison with the phase III-derived historical
controls showed a statistically improved outcome in CR
(30% vs 9%; P ¼ .0006) and day-100 survival (46% vs 25%;
P ¼ .006) [25].
As mentioned above, encouraging results observed with
DF in treatment trials have also led to further investigation of
its use as prophylaxis for VOD after HSCT. A number ofprospective historically controlled trials have reported
beneﬁts with DF prophylaxis in children at high risk of
developing VOD [26-29]. These early studies are also strongly
supported by the recent prospective, multicenter, phase II/III
studies in the European Union [5]. This trial randomized 360
children (<18 years) undergoing myeloablative HSCT to
receive either prophylactic DF from conditioning to 30 days
post-HSCT or no prophylaxis (control group). In the intent-
to-treat analysis (n ¼ 356), there was a 40% reduction in
VOD by day-30 post-HSCT in patients receiving prophylactic
DF compared with the control group (12% vs 20%; P ¼ .051).
Another important observationwas that the mortality rate at
100 days was 4 times higher in patients who developed VOD
than in those without VOD (25% vs 6%; P < .0001). It is also
noteworthy that the incidence of acute graft-versus-host
disease, which was a secondary endpoint in the trial, was
also signiﬁcantly lower in the DF prophylaxis arm, an
observation consistent with similar ﬁndings in treatment
studies, where rates of graft-versus-host disease were
remarkably low.
To date, DF has been used in more than 240 trans-
plantation centers across 33 countries as a result of a large
compassionate-use program and the ongoing named patient
programs. Based on an overall experience in more than 1,800
patients, DF continues to demonstrate remarkable safety and
tolerability despite a very ill patient population, with
manageable toxicities and low rates of attributable hemor-
rhage [30].FUTURE DIRECTIONS
Despite the promising results from clinical trials with DF
as treatment and prevention of VOD, day-100 mortality from
sVOD remains unacceptably high. Recent observations have
shown that delayed initiation of treatment is associated with
a worse outcome, highlighting the importance of early
intervention once a VOD diagnosis is established [25]. The
role of DF in the VOD treatment paradigm may, in fact, be
optimized with its use in early disease or as prophylaxis.
Additional prospective studies in VOD prevention are now
planned in adult HSCT populations and speciﬁc high-risk
settings. Elevations of von Willebrand factor, thrombomo-
dulin, E-selectin, and soluble ICAM-1 before and early after
allogeneic transplantation may be useful in predicting VOD
in patients receiving sirolimus [31] as graft-versus-host
disease prophylaxis and could lead to pre-emptive treat-
ment or prevention trials based on these and other
biomarkers [1]. Finally, additional therapies, such as low-
molecular-weight heparin, N-acetyl cysteine, antithrombin
III, and other novel antithrombotics, may warrant further
investigation in combination with DF [1,32].ACKNOWLEDGMENTS
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